newsfilter
← Latest News
Business Wire·

Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreeme